These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 24835327)

  • 21. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm.
    Diletti R; Onuma Y; Farooq V; Gomez-Lara J; Brugaletta S; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn R; Smits P; Koolen J; Meredith I; Li D; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    J Am Coll Cardiol; 2011 Jul; 58(3):258-64. PubMed ID: 21737016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the serial changes of vessel wall contents in atherosclerotic coronary lesion with bioresorbable everolimus-eluting vascular scaffolds using Shin's method: an IVUS study.
    Shin ES; Garcia-Garcia HM; Garg S; Ligthart J; Thuesen L; Dudek D; Ormiston JA; Serruys PW
    Int J Cardiovasc Imaging; 2011 Oct; 27(7):931-7. PubMed ID: 21080074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial.
    Kereiakes DJ; Ellis SG; Popma JJ; Fitzgerald PJ; Samady H; Jones-McMeans J; Zhang Z; Cheong WF; Su X; Ben-Yehuda O; Stone GW
    Am Heart J; 2015 Oct; 170(4):641-651.e3. PubMed ID: 26386787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up.
    Gomez-Lara J; Brugaletta S; Farooq V; van Geuns RJ; De Bruyne B; Windecker S; McClean D; Thuesen L; Dudek D; Koolen J; Whitbourn R; Smits PC; Chevalier B; Morel MA; Dorange C; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2011 Jul; 4(7):789-99. PubMed ID: 21777888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
    Onuma Y; Serruys PW; Gomez J; de Bruyne B; Dudek D; Thuesen L; Smits P; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia H; Ormiston JA;
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):3-12. PubMed ID: 21413120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioresorbable vascular scaffold (BVS) for in-stent chronic total occlusion: Antegrade recanalization and IVUS-guided BVS implantation by radial access.
    Medda M; Casilli F; Bande M; Latini MG; Ghommidh M; Del Furia F; Inglese L
    Cardiovasc Revasc Med; 2016; 17(1):63-5. PubMed ID: 26797428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
    JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions.
    Okamoto N; Ueda H; Yoshimura T; Chamaria S; Bhatheja S; Vengrenyuk Y; Rabiei S; Barrientos Y; Kapur V; Barman N; Sweeny J; Baber U; Mehran R; Sharma SK; Kini AS
    J Invasive Cardiol; 2018 Jul; 30(7):251-255. PubMed ID: 29656280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early-Stage Vascular Response between Bare Metal Stent and Drug-Free Bioresorbable Vascular Scaffold in the Small-Sized Peripheral Artery: A Preclinical Study in Porcine Femoral Arteries.
    Ahn J; Rha SW; Choi BG; Park S; Choi WG; Li HU; Yu H; Byeon J; Moon SK; Do ST
    Ann Vasc Surg; 2019 Oct; 60():388-396. PubMed ID: 31200063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Very late vasomotor responses and gene expression with bioresorbable scaffolds and metallic drug-eluting stents.
    Koh JS; Gogas BD; Kumar S; Benham JJ; Sur S; Spilias N; Kumar A; Giddens DP; Rapoza R; Kereiakes DJ; Stone G; Jo H; Samady H
    Catheter Cardiovasc Interv; 2021 Oct; 98(4):723-732. PubMed ID: 34164905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance.
    Mattesini A; Secco GG; Dall'Ara G; Ghione M; Rama-Merchan JC; Lupi A; Viceconte N; Lindsay AC; De Silva R; Foin N; Naganuma T; Valente S; Colombo A; Di Mario C
    JACC Cardiovasc Interv; 2014 Jul; 7(7):741-50. PubMed ID: 25060016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study.
    Brugaletta S; Garcia-Garcia HM; Diletti R; Gomez-Lara J; Garg S; Onuma Y; Shin ES; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn R; Dorange C; Veldhof S; Rapoza R; Sudhir K; Bruining N; Ormiston JA; Serruys PW
    EuroIntervention; 2011 Apr; 6(9):1110-6. PubMed ID: 21518685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial.
    Sarno G; Bruining N; Onuma Y; Garg S; Brugaletta S; De Winter S; Regar E; Thuesen L; Dudek D; Veldhof S; Dorange C; Garcia-Garcia HM; Ormiston JA; Serruys PW
    Int J Cardiovasc Imaging; 2012 Jan; 28(1):51-8. PubMed ID: 21213050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioresorbable vascular scaffolds versus everolimus-eluting stents: a biomechanical analysis of the ABSORB III Imaging substudy.
    Kumar A; Gogas BD; Thompson EW; Burnett GM; Molony D; Hosseini H; Chandran K; Lefieux A; Honda Y; Lee JM; Serruys PW; Kereiakes DJ; Stone GW; Samady H;
    EuroIntervention; 2020 Dec; 16(12):e989-e996. PubMed ID: 32091401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
    Brugaletta S; Gomez-Lara J; Serruys PW; Farooq V; van Geuns RJ; Thuesen L; Dudek D; Koolen J; Chevalier B; McClean D; Windecker S; Smits PC; de Bruyne B; Whitbourn R; Meredith I; van Domburg RT; Sihan K; de Winter S; Veldhof S; Miquel-Hebert K; Rapoza R; Garcia-Garcia HM; Ormiston JA; Bruining N
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1281-9. PubMed ID: 22192369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.